Table 1

B-cell targeting biologics in clinical development

Target

Therapeutic

Format

Mechanism

Indication

Clinical stageaa

CD20

Rituximab

Chimeric

Depletion

RA

Approved

IgG1

ADCC, CDC

Pemphigus

Phase 3

AIHA

Phase 3

ITP

Phase 3 (newly diagnosed)

ITP

Phase 2

Acute IPF

Phase 1/2 (with plasma exchange)

AIR

Phase 1

Ofatumumab

Humanized

Depletion

RA

Phase 3

IgG1

ADCC, CDC

RRMS

Phase 2

RRMS

Phase 2 (subcutaneously)

Ocrelizumab

Humanized

Depletion

RRMS

Phase 3

IgG1

ADCC, CDC

PPMS

Phase 3

SLE

Phase 3

Veltuzumab

Humanized

Depletion

RA

Phase 2

IgG1

ADCC, CDC

ITP

Phase 1/2

CD19

MEDI-551

Humanized

Depletion

SSc

Phase 1

IgG1 afucosylated

ADCC

RRMS

Phase 1

CD22

Epratuzumab

Humanized

Partial depletion

SLE

Phase 3

IgG1

B-cell activation

BAFF

Belimumab

Human

Ligand neutral

SLE

Approved

IgG1

Survival

SLE

Phase 3 (subcutaneously)

ITP

Phase 2

MG

Phase 2

Tabalumab

Human

Ligand neutral

SLE

Phase 3 (subcutaneously)

IgG4

Survival

RA

Phase 2

Blisibimod

Peptibody

Ligand neutral

SLE

Phase 3

ITP

Phase 2/3

BAFF/APRIL

Atacicept

Receptor

Ligand neutral

SLE

Phase 2/3

Fc fusion

Survival

CD40L

CDP7657

Pegylated

Co-stimulation

SLE

Phase 1

Fab

Blockade

B7RP1

AMG-557

Human

Co-stimulation

SCLE

Phase 1

IgG

Blockade

Psoriasis

Phase 1

SLE

Phase 1

ICOS

MEDI-570

Human

Depletion

SLE

Phase 1

IgG1 afucosylated

ADCC

IL-21

NN8828

Humanized

Ligand neutral

RA

Phase 1

IgG1


ADCC, antibody-dependent cellular cytotoxicity; AIHA, autoimmune hemolytic anemia; AIR, autoimmune retinopathy; APRIL, a proliferation-inducing ligand; BAFF, B-cell activating factor; CD40L, CD40 ligand; CDC, complement-dependent cytotoxicity; IPF, idiopathic pulmonary fibrosis; ITP, idiopathic thrombocytopenia purpura; MG, myasthenia gravis; PPMS, primary progressive multiple sclerosis; RA, rheumatoid arthritis; RRMS, relapsing remitting multiple sclerosis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis; SSLE, subacute cutaneous lupus erythematosus. aSource for clinical trial status: www.clinicaltrials.gov webcite (as of February 2013).

Bl├╝ml et al. Arthritis Research & Therapy 2013 15(Suppl 1):S4   doi:10.1186/ar3906